Skip to content

Francesco Saldarini

3 papers in the library · 101 citations · publishing 2022-2023

Papers

Sort Most recent Most cited

Associations between chronic stress, attention, working memory, and mindful acceptance in the context of Monitor and Acceptance Theory: a direct replication and exploratory cross-sectional study

August 4, 2023 Francesco Saldarini, Kaho Yamasaki, Hiromitsu Miyata preprint

Objectives: Mindfulness-based interventions (MBIs) can reduce chronic stress, but their therapeutic mechanisms remain unclear. MBIs may train attention monitoring and acceptance skills that have been impaired by chronic stress exposure, and the interaction between these skills might lead to chronic stress reduction. In the present study, we aimed at directly replicating one of the few existing...

A Critical Review of the Monitor and Acceptance Theory of Mindfulness

Mindfulness June 1, 2023 Luca Simione, Francesco Saldarini

Abstract: In 2017, Lindsay and Creswell proposed the Monitor and Acceptance Theory (MAT) of mindfulness, which proposed a unified and testable framework for interpreting and predicting different mindfulness effects on attention, affective reactivity, emotion regulation, and health-related variables. MAT identifies two basic mindfulness skills: attention monitoring and acceptance. The theory is...

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

Journal of Psychopharmacology 2022 James Rucker, Lindsey Marwood, Riikka-Liisa Johanna Ajantaival et al. 101 citations

Background: Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. Aim: The aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised...

DOI: 10.1177/02698811211064720 (opens in new tab) Psilocybin Placebo Adverse effect Randomized controlled trial +2